Short-term treatment with imetelstat sensitizes hematopoietic malignant cells to a genotoxic agent via suppression of the telomerase-mediated DNA repair process

References

• Cong YS, Wright WE, Shay JW. Human telomerase and its regulation. Microbiol Mol Biol Rev. 2002;66(3):407–425.
   PubMed Web of Science ®Google Scholar
• Lavelle F, Riou JF, Laoui A, et al. Telomerase: a therapeutic target for the third millennium? Crit Rev Oncol Hematol. 2000;34(2):111–126.
   PubMed Web of Science ®Google Scholar
• Shay JW, Bacchetti S. A survey of telomerase activity in human cancer. Eur J Cancer. 1997;33(5):787–791.
   PubMed Web of Science ®Google Scholar
• Kim NW, Piatyszek MA, Prowse KR, et al. Specific association of human telomerase activity with immortal cells and cancer. Science. 1994;266(5193):2011–2015.
   PubMed Web of Science ®Google Scholar
• Masutomi K, Possemato R, Wong JMY, et al. The telomerase reverse transcriptase regulates chromatin state and DNA damage responses. Proc Natl Acad Sci Usa. 2005;102(23):8222–8227.
   PubMed Web of Science ®Google Scholar
• Li YH, Tergaonkar V. Noncanonical functions of telomerase: implications in telomerase-targeted cancer therapies. Cancer Res. 2014;74(6):1639–1644.
   PubMed Web of Science ®Google Scholar
• Sharma GG, Hall EJ, Dhar S, et al. Telomere stability correlates with longevity of human beings exposed to ionizing radiations. Oncol Rep. 2003;10(6):1733–1736.
   PubMed Web of Science ®Google Scholar
• Onozawa M, Zhang Z, Kim YJ, et al. Repair of DNA double-strand breaks by templated nucleotide sequence insertions derived from distant regions of the genome. Proc Natl Acad Sci Usa. 2014;111(21):7729–7734.
   PubMed Web of Science ®Google Scholar
• Herbert B-S, Gellert GC, Hochreiter A, et al. Lipid modification of GRN163, an N3'->P5' thio-phosphoramidate oligonucleotide, enhances the potency of telomerase inhibition. Oncogene. 2005;24(33):5262–5268.
   PubMed Web of Science ®Google Scholar
• Schrank Z, Khan N, Osude C, et al. Oligonucleotides targeting telomeres and telomerase in cancer. Molecules. 2018;23(9):2267.
   PubMed Web of Science ®Google Scholar
• Tefferi A. Telomerase inhibitor imetelstat in essential thrombocythemia and myelofibrosis. N Engl J Med. 2015;373(26):2580–2581.
   PubMed Web of Science ®Google Scholar
• Baerlocher GM, Oppliger Leibundgut E, Ottmann OG, et al. Telomerase inhibitor imetelstat in patients with essential thrombocythemia. N Engl J Med. 2015;373(10):920–928.
   PubMed Web of Science ®Google Scholar
• Tefferi A, Lasho TL, Begna KH, et al. A pilot study of the telomerase inhibitor imetelstat for myelofibrosis. N Engl J Med. 2015;373(10):908–919.
   PubMed Web of Science ®Google Scholar
• Djojosubroto MW, Chin AC, Go N, et al. Telomerase antagonists GRN163 and GRN163L inhibit tumor growth and increase chemosensitivity of human hepatoma. Hepatology. 2005;42(5):1127–1136.
   PubMed Web of Science ®Google Scholar
• Goldblatt EM, Gentry ER, Fox MJ, et al. The telomerase template antagonist GRN163L alters MDA-MB-231 breast cancer cell morphology, inhibits growth, and augments the effects of paclitaxel. Mol Cancer Ther. 2009;8(7):2027–2035.
   PubMed Web of Science ®Google Scholar
• Wu X, Smavadati S, Nordfjäll K, et al. Telomerase antagonist imetelstat inhibits esophageal cancer cell growth and increases radiation-induced DNA breaks. Biochim Biophys Acta. 2012;1823(12):2130–2135.
   PubMed Web of Science ®Google Scholar
• Wu X, Zhang J, Yang S, et al. Telomerase antagonist imetelstat increases radiation sensitivity in esophageal squamous cell carcinoma. Oncotarget. 2017;8(8):13600–13619.
   PubMedGoogle Scholar
• Hidaka D, Onozawa M, Hashiguchi J, et al. Wilms tumor 1 expression at diagnosis correlates with genetic abnormalities and polymorphism but is not independently prognostic in acute myelogenous leukemia: a Hokkaido leukemia net study. Clin Lymphoma Myeloma Leuk. 2018;18(11):e469–479.
   Web of Science ®Google Scholar
• Kanda Y. Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Bone Marrow Transplant. 2013;48(3):452–458.
   PubMed Web of Science ®Google Scholar
• Morrison SJ, Prowse KR, Ho P, et al. Telomerase activity in hematopoietic cells is associated with self-renewal potential. Immunity. 1996;5(3):207–216.
   PubMed Web of Science ®Google Scholar
• Aalbers AM, Calado RT, Young NS, et al. Telomere length and telomerase complex mutations in pediatric acute myeloid leukemia. Leukemia. 2013;27(8):1786–1789.
   PubMed Web of Science ®Google Scholar
• Bernard L, Belisle C, Mollica L, et al. Telomere length is severely and similarly reduced in JAK2V617F-positive and -negative myeloproliferative neoplasms. Leukemia. 2009;23(2):287–291.
   PubMed Web of Science ®Google Scholar
• Drummond MW, Hoare SF, Monaghan A, et al. Dysregulated expression of the major telomerase components in leukaemic stem cells. Leukemia. 2005;19(3):381–389.
   PubMed Web of Science ®Google Scholar
• Gessner A, Thomas M, Castro PG, et al. Leukemic fusion genes MLL/AF4 and AML1/MTG8 support leukemic self-renewal by controlling expression of the telomerase subunit TERT. Leukemia. 2010;24(10):1751–1759.
   PubMed Web of Science ®Google Scholar
• Allegra A, Innao V, Penna G, et al. Telomerase and telomere biology in hematological diseases: a new therapeutic target. Leuk Res. 2017;56:60–74.
   PubMed Web of Science ®Google Scholar
• Jones CH, Pepper C, Baird DM. Telomere dysfunction and its role in haematological cancer. Br J Haematol. 2012;156(5):573–587.
   PubMed Web of Science ®Google Scholar
• Kyo S, Takakura M, Fujiwara T, et al. Understanding and exploiting hTERT promoter regulation for diagnosis and treatment of human cancers. Cancer Sci. 2008;99(8):1528–1538.
   PubMed Web of Science ®Google Scholar
• Ropio J, Merlio JP, Soares P, et al. Telomerase activation in hematological malignancies. Genes (Basel). 2016;7(9):61.
   Web of Science ®Google Scholar
• Jafri MA, Ansari SA, Alqahtani MH, et al. Roles of telomeres and telomerase in cancer, and advances in telomerase-targeted therapies. Genome Med. 2016;8(1):69.
   PubMedGoogle Scholar
• Shammas MA, Koley H, Bertheau RC, et al. Telomerase inhibitor GRN163L inhibits myeloma cell growth in vitro and in vivo. Leukemia. 2008;22(7):1410–1418.
   PubMed Web of Science ®Google Scholar
• Burchett KM, Yan Y, Ouellette MM. Telomerase inhibitor Imetelstat (GRN163L) limits the lifespan of human pancreatic cancer cells. PLoS One. 2014;9(1):e85155.
   PubMed Web of Science ®Google Scholar
• Shay JW. Role of telomeres and telomerase in aging and cancer. Cancer Discov. 2016;6(6):584–593.
   PubMed Web of Science ®Google Scholar
• Thompson CAH, Gu A, Yang SY, et al. Transient telomerase inhibition with imetelstat impacts DNA damage signals and cell-cycle kinetics. Mol Cancer Res. 2018;16(8):1215–1225.
   PubMed Web of Science ®Google Scholar
• Nergadze SG, Santagostino MA, Salzano A, et al. Contribution of telomerase RNA retrotranscription to DNA double-strand break repair during mammalian genome evolution. Genome Biol. 2007;8(12):R260.
   PubMed Web of Science ®Google Scholar
• Nergadze SG, Rocchi M, Azzalin CM, et al. Insertion of telomeric repeats at intrachromosomal break sites during primate evolution. Genome Res. 2004;14(9):1704–1710.
   PubMed Web of Science ®Google Scholar
• Ouenzar F, Lalonde M, Laprade H, et al. Cell cycle-dependent spatial segregation of telomerase from sites of DNA damage. J Cell Biol. 2017;216(8):2355–2371.
   PubMed Web of Science ®Google Scholar
• Pennaneach V, Putnam CD, Kolodner RD. Chromosome healing by de novo telomere addition in Saccharomyces cerevisiae. Mol Microbiol. 2006;59(5):1357–1368.
   PubMed Web of Science ®Google Scholar
• Cong Y, Shay JW. Actions of human telomerase beyond telomeres. Cell Res. 2008;18(7):725–732.
   PubMed Web of Science ®Google Scholar
• Uziel O, Beery E, Dronichev V, et al. Telomere shortening sensitizes cancer cells to selected cytotoxic agents: in vitro and in vivo studies and putative mechanisms. PLoS One. 2010;5(2):e9132.
   PubMed Web of Science ®Google Scholar